CryoLife
This article was originally published in The Gray Sheet
Executive Summary
Investigational device exemption will be filed with FDA in the third quarter for an injectable spinal disc replacement system, CEO Steven Anderson predicts at recent U.S. Bancorp Piper Jaffray conference. The protein hydrocell device reaches maximum strength in three to four minutes and will compete with spinal fusion cages